相关实验视频

Updated: Jun 18, 2025

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Phage Therapy Application to Counteract Pseudomonas aeruginosa Infection in Cystic Fibrosis Zebrafish Embryos

Published on: May 12, 2020

难以治疗的伪白:成功地用cefepime-zidebactam进行救援疗法

Anjely Sebastian¹, Shivdas Naik¹, Muralidhar Varma¹

¹Department of Infectious Diseases, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal 576104, India.

Transactions of the Royal Society of Tropical Medicine and Hygiene

|July 27, 2024

概括

塞费皮姆-齐德巴克坦为由抗卡巴因耐药的Pseudomonas aeruginosa (CRPa) 引起的严重感染提供了一个新的治疗选择. 一名患有多种药物耐药性CRPa感染的年轻烧伤患者在45天的Cefepime-zidebactam治疗后成功康复.

科学领域:

传染性疾病传染性疾病
抗微生物耐药性抗微生物耐药性
临床治疗学临床治疗学

背景情况:

耐卡巴尼姆的Pseudomonas aeruginosa (CRPa) 感染由于治疗选择有限,造成了重大治疗挑战.
Pseudomonas aeruginosa 是医院感染的常见原因,对卡巴胺的耐药性是全球日益关注的问题.
严重的CRPa感染的有效管理,特别是免疫功能低下或重症患者,需要新的抗菌药物策略.

研究的目的:

评估塞费皮姆-齐德巴克坦作为复杂的抗卡巴胺抗性Pseudomonas aeruginosa感染的救援疗法的疗效和安全性.
报告患有广泛热灼伤和严重多部位CRPa感染的儿科患者的临床结果.
要突出cefepime-zidebactam在治疗常规抗生素失败的感染中的潜在作用.

主要方法:

一个15岁男孩的病例报告,身体表面总面积的56%是热烧伤.
二次性并发症的管理,包括皮肤和软组织感染,细菌病,肺流和由CRPa引起的内炎.
在证明对所有常用抗生素不敏感后,用cefepime-zidebactam治疗45天.

主要成果:

该患者出现了严重的,多药耐药的CRPa感染,涉及多个器官系统.
塞费皮姆-齐德巴克坦治疗是作为救援治疗的开始,因为缺乏易受感染的替代品.
患者在45天的cefepime-zidebactam疗程后实现了完全的临床康复.

结论:

塞费皮姆-齐德巴克坦在患有危及生命,广泛抗药性Pseudomonas aeruginosa感染的儿科患者中表现出成功的临床结果.
这种新型组合抗生素可以成为一种有价值的治疗选择,用于在其他抗微生物药物无效时在关键感染中进行救援治疗.
需要进一步研究塞费皮姆-齐德巴克坦对抗格拉姆阴性细菌感染的作用.

关键词:

根据CRPA的规定,我们可以使用CRPA.烧伤,烧伤,烧伤就是一个问题.这种疾病被称为 Pseudomonas.这就是Zidebactam.

更多相关视频

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung

Published on: June 5, 2012

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

相关概念视频

Pneumonia IV: Management

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

Pulmonary Tuberculosis V

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...

Combined Effects of Drugs: Synergism

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...